During the COVID-19 crisis, managed care professionals are facing unique challenges to deliver patient care. This resource center is designed to aggregate timely information for AMCP members and stakeholders.
AMCP Format 4.1 includes new sections describing the evidence needs of HCDMs for unapproved products nearing the end of the product development pipeline, as well as unapproved uses of existing products for which FDA approval is being sought.
The Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) was established to address anticipated needs for post-marketed evidence generation for novel biologics, their corresponding biosimilars and other related products.
This forum identified key actions that can support access to and the appropriate management of treatments for rare diseases within the U.S. health care system.
A type of B-cell non-Hodgkin lymphoma (cancer of the immune system) that is usually aggressive (fast-growing). It is the most common type of non-Hodgkin lymphoma, and is marked by rapidly growing tumors in the lymph nodes, spleen, liver, bone marrow, or other organs. AMCP is pleased to work with Monjuvi to offer these resources to you.
